Catalysts for Keytruda
125 tracked
Apr 30, 2026
phase 2 completion
Merck & Co Inc — pembrolizumab (Phase II Trial Completion)
pembrolizumab
→
Apr 27, 2026
phase 1 initiation
National Institute of Neurological Disorders and Stroke — pembrolizumab (Phase I Trial Initiation)
pembrolizumab
→
Apr 6, 2026
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Feb 10, 2026
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Nov 21, 2025
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Jul 24, 2025
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Jun 12, 2025
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Jun 6, 2025
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Jun 3, 2025
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
May 22, 2025
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Apr 21, 2025
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Mar 19, 2025
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Jan 28, 2025
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Dec 11, 2024
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Nov 20, 2024
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Sep 17, 2024
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Aug 7, 2024
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Jul 31, 2024
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Jun 17, 2024
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Jun 7, 2024
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Mar 11, 2024
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Jan 25, 2024
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Jan 12, 2024
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Dec 15, 2023
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Dec 15, 2023
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Nov 16, 2023
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Nov 7, 2023
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Oct 31, 2023
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Oct 31, 2023
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→
Oct 23, 2023
approval
KEYTRUDA (PEMBROLIZUMAB) — FDA approval
pembrolizumab
→